Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

Author： Yasufuku Tomihiko   Shigemura Katsumi   Matsumoto Osamu   Arakawa Soichi   Fujisawa Masato  

Publisher： Springer Publishing Company

ISSN： 1341-321X

Source： Journal of Infection and Chemotherapy, Vol.16, Iss.3, 2010-06, pp. : 200-205

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Paclitaxel, Estramustine and Carboplatin Combination Chemotherapy after Initial Docetaxel-Based Chemotherapy in Castration-Resistant Prostate Cancer

By  

Oncology, Vol. 76, Iss. 6, 2009-05 ,pp. : 442-446

Karger

Access to resources Recommend Favorite

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 281-287

Karger

Access to resources Recommend Favorite

Oral Combination of Cyclophosphamide, Uracil plus Tegafur and Estramustine for Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 60, Iss. 1, 2000-12 ,pp. : 49-54

Karger

Access to resources Recommend Favorite

Role of Chemotherapy in Hormone-Refractory Prostate Cancer

By  

Urologia Internationalis, Vol. 70, Iss. 1, 2003-02 ,pp. : 1-14

Karger

Access to resources Recommend Favorite

Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer

By  

Oncology Research and Treatment, Vol. 28, Iss. 11, 2005-10 ,pp. : 573-578

Karger

Access to resources Recommend Favorite